Related Experiment Video
Updated: Mar 27, 2026
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Targeting c-MET by LY2801653 for treatment of cholangiocarcinoma
Samarpita Barat1, Przemyslaw Bozko1, Xi Chen1
1Department of Internal Medicine I, Medical University Hospital, Otfried-Mueller-Str. 10, Tübingen, Germany.
Abstract:
Palliative treatment options for human cholangiocarcinoma (CCC) are quite limited and new therapeutic strategies are of utmost need. c-MET has been shown to be deregulated in many cancers, but the role of c-MET in the carcinogenesis of CCC remains unclear. The main purpose of this study is to evaluate the expression and also to investigate the role of c-MET and its effective inhibition for the treatment of CCC. In this study we investigated the effects of LY2801653, a small-molecule inhibitor with potent activity against MET kinase, in human CCC cell lines and in vivo using a xenograft mouse model. We have investigated the role of c-MET and its inhibitory effects on migration, invasion, colony formation, MET downstream targets, and CCC tumor growth. We also analyzed the role of apoptosis and senescence as well as the influence of hypoxia in this context. c-MET and p-MET were expressed in 72% and 12.5% of human CCC tissues and in TFK-1, SZ-1 cell lines. MET inhibition was achieved by blocking phosphorylation of MET with LY2801653 and subsequent down regulation of c-MET downstream targets. Treatment showed in a xenograft model potent anti-tumor activity. LY2801653 is an effective inhibitor and suppress the proliferation of CCC cells as well as the growth of xenograft tumors. Therefore, inhibition of c-MET could be a possible alternative approach for the treatment of human CCC. © 2016 Wiley Periodicals, Inc.
Insights
New research indicates that inhibiting c-MET (mesenchymal-epithelial transition factor receptor tyrosine kinase) shows promise for treating human cholangiocarcinoma (CCC). This targeted therapy suppressed cancer cell proliferation and xenograft tumor growth in preclinical models.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Palliative treatment options for human cholangiocarcinoma (CCC) are limited, necessitating novel therapeutic strategies.
- The role of c-MET (mesenchymal-epithelial transition factor receptor tyrosine kinase) in CCC carcinogenesis is not well understood.
- c-MET deregulation is implicated in various cancers, suggesting its potential relevance in CCC.
Purpose of the Study:
- To evaluate c-MET expression in human CCC.
- To investigate the role of c-MET in CCC development and progression.
- To assess the efficacy of c-MET inhibition as a therapeutic strategy for CCC.
Main Methods:
- Utilized LY2801653, a small-molecule MET kinase inhibitor, in human CCC cell lines and a xenograft mouse model.
- Assessed the impact of MET inhibition on cell migration, invasion, colony formation, and downstream signaling.
- Analyzed effects on apoptosis, senescence, hypoxia, and tumor growth in vivo.
Main Results:
- c-MET and phosphorylated MET (p-MET) were expressed in a significant percentage of human CCC tissues and cell lines.
- LY2801653 effectively inhibited MET phosphorylation, downregulating downstream targets and suppressing CCC cell proliferation.
- MET inhibition demonstrated potent anti-tumor activity in a xenograft mouse model, reducing tumor growth.
Conclusions:
- c-MET is expressed in human CCC and plays a role in its progression.
- LY2801653 effectively inhibits c-MET signaling, suppressing CCC cell proliferation and tumor growth.
- Inhibition of c-MET represents a potential therapeutic approach for human cholangiocarcinoma.
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
